Abbott Reports Second-Quarter 2015 Results

- SECOND-QUARTER ADJUSTED AND GAAP EPS FROM CONTINUING OPERATIONS OF $0.52, ABOVE PREVIOUS GUIDANCE RANGE

- SECOND-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH

- ADVANCES SEVERAL NEW TECHNOLOGIES IN ITS MEDICAL DEVICES AND DIAGNOSTICS BUSINESSES

Jul 22, 2015, 07:45 ET from Abbott

ABBOTT PARK, Ill., July 22, 2015 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2015.

  • Second-quarter worldwide sales of $5.2 billion increased 10.8 percent on an operational basis and 2.2 percent on a reported basis. Worldwide sales increased 6.4 percent excluding the impact of 2014 acquisitions and foreign exchange.
  • Diluted EPS from continuing operations on both an adjusted and GAAP basis was $0.52 in the second quarter.
  • Abbott's full-year 2015 adjusted EPS guidance range for continuing operations remains unchanged at $2.10 to $2.20. Projected full-year 2015 EPS for continuing operations under GAAP is $1.50 to $1.60.
  • Second-quarter gross margin ratio was ahead of expectations, primarily driven by continued improvements in Diagnostics and Nutrition.
  • In the second quarter, Abbott received European approval for Absorb GT1TM, which combines the world's first fully dissolving stent with a next-generation delivery catheter; completed submissions for regulatory approval of Absorb in Japan and the U.S.; submitted for U.S. regulatory approval of its FreeStyle® Libre Pro Flash Glucose Monitoring System for professional use; and received U.S. FDA clearance for a first-of-its-kind blood test for its i-STAT® handheld system to aid in detecting early pregnancy in emergency situations.

"We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said Miles D. White, chairman and chief executive officer, Abbott. "We're well on track to achieve our financial objectives for the year despite a challenging currency environment."

SECOND-QUARTER BUSINESS OVERVIEW

Note: Prior year financial results have been adjusted to exclude the sales from Abbott's developed markets branded generics pharmaceuticals and animal health businesses that were sold to Mylan and Zoetis, respectively, in the first quarter 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.

Following are sales by business segment and commentary for the second quarter and first half of the year:

Total Company
($ in millions)









% Change vs. 2Q14



Sales 2Q15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total *


1,592


3,578


5,170


3.1


14.2


1.8


10.8


2.2

Nutrition


729


988


1,717


0.6


6.3


(1.9)


3.9


(0.8)

Diagnostics


350


827


1,177


7.6


9.0


(4.3)


8.7


(1.0)

Established Pharmaceuticals

--


977


977


 n/a 


46.0


31.3


46.0


31.3

Medical Devices


505


784


1,289


3.0


3.1


(11.2)


3.1


(6.1)


* Total Abbott Sales from continuing operations include Other Sales of $10 million.

 









% Change vs. 1H14



Sales 1H15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total *


3,094


6,973


10,067


2.5


13.9


2.6


10.4


2.6

Nutrition


1,414


1,972


3,386


--


8.7


1.2


5.0


0.7

Diagnostics


677


1,593


2,270


6.6


7.6


(4.6)


7.3


(1.6)

Established Pharmaceuticals

--


1,874


1,874


 n/a 


44.5


31.5


44.5


31.5

Medical Devices


990


1,525


2,515


3.3


1.4


(11.7)


2.1


(6.3)


* Total Abbott Sales from continuing operations include Other Sales of $22 million.

n/a = Not Applicable.

Note: Operational growth reflects percentage change over the prior year excluding the impact of exchange rates.

Second-quarter 2015 worldwide sales of $5.2 billion increased 10.8 percent on an operational basis and 2.2 percent on a reported basis, including an unfavorable 8.6 percent effect of foreign exchange. Worldwide sales increased 6.4 percent excluding the impact of 2014 acquisitions and foreign exchange, driven by strong performance in Established Pharmaceuticals and Diagnostics.

International sales increased 14.2 percent on an operational basis and 1.8 percent on a reported basis in the second quarter.

Emerging market sales increased 20.6 percent on an operational basis and 10.0 percent on a reported basis in the second quarter. Excluding the impact of 2014 acquisitions and foreign exchange, emerging market sales increased double digits in the quarter.  

Nutrition
($ in millions)         









% Change vs. 2Q14



Sales 2Q15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


729


988


1,717


0.6


6.3


(1.9)


3.9


(0.8)

Pediatric


401


567


968


2.0


5.2


(1.2)


3.9


0.1

Adult


328


421


749


(1.1)


7.7


(2.7)


3.9


(2.0)

 









% Change vs. 1H14



Sales 1H15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


1,414


1,972


3,386


--


8.7


1.2


5.0


0.7

Pediatric


786


1,144


1,930


3.2


8.4


2.3


6.3


2.7

Adult


628


828


1,456


(3.8)


9.2


(0.3)


3.5


(1.8)

Worldwide Nutrition sales increased 3.9 percent in the second quarter on an operational basis and decreased 0.8 percent on a reported basis, including an unfavorable 4.7 percent effect of foreign exchange.

Worldwide Pediatric Nutrition sales increased 3.9 percent on an operational basis and 0.1 percent on a reported basis in the quarter, including an unfavorable 3.8 percent effect of foreign exchange. Growth in the quarter was driven by double-digit operational growth in China and several countries in Latin America, partially offset by market dynamics in certain Asian countries. Abbott continues to broaden its pediatric nutrition portfolio in China and recently launched an organic version of its infant formula Eleva TM into the premium segment of the Chinese infant formula market. In the U.S., Abbott provided parents with another formula choice for their babies by launching Similac® Advance® non-GMO.

Worldwide Adult Nutrition sales increased 3.9 percent on an operational basis and decreased 2.0 percent on a reported basis in the quarter, including an unfavorable 5.9 percent effect of foreign exchange. Sales growth in the quarter was led by international performance, including double-digit operational growth in Latin America, as Abbott continues to shape and grow its priority international markets. As expected, U.S. Adult Nutrition sales were impacted by competitive and market dynamics, primarily in the institutional segment.

Diagnostics
($ in millions)









% Change vs. 2Q14



Sales 2Q15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total 


350


827


1,177


7.6


9.0


(4.3)


8.7


(1.0)

Core Laboratory


206


741


947


8.6


8.4


(4.9)


8.4


(2.3)

Molecular


50


66


116


(3.8)


18.3


2.6


8.4


(0.3)

Point of Care


94


20


114


12.7


7.3


(1.7)


11.6


9.8

 









% Change vs. 1H14



Sales 1H15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total 


677


1,593


2,270


6.6


7.6


(4.6)


7.3


(1.6)

Core Laboratory


391


1,422


1,813


5.3


6.9


(5.3)


6.6


(3.2)

Molecular


98


129


227


(0.4)


14.2


0.4


7.9


--

Point of Care


188


42


230


13.7


12.6


4.5


13.5


11.9

Worldwide Diagnostics sales increased 8.7 percent in the second quarter on an operational basis and decreased 1.0 percent on a reported basis, including an unfavorable 9.7 percent effect of foreign exchange. This business continues to deliver above-market growth across emerging and developed markets.

Core Laboratory Diagnostics sales increased 8.4 percent in the quarter on an operational basis and decreased 2.3 percent on a reported basis, including an unfavorable 10.7 percent effect of foreign exchange. Above-market sales growth this quarter, including double-digit operational sales growth in emerging markets, was driven by share gains in the U.S. and internationally as this business continues to win key new accounts with its customer-focused solutions.

Molecular Diagnostics sales increased 8.4 percent in the quarter on an operational basis and decreased 0.3 percent on a reported basis, including an unfavorable 8.7 percent effect of foreign exchange. Abbott's core focus area of infectious disease testing, which represents approximately 55 percent of its Molecular Diagnostics sales, increased double digits in the quarter on an operational basis. As expected, U.S. growth was impacted by continued market dynamics in the oncology business and the planned scale down of the genetics business.

Point of Care Diagnostics sales increased 11.6 percent in the quarter on an operational basis as this business continues to build and expand its presence in targeted developed and emerging markets. Sales increased 9.8 percent on a reported basis, including an unfavorable 1.8 percent effect of foreign exchange. In the second quarter, Abbott received U.S. FDA clearance for its i-STAT Total β-hCG test, a first-of-its-kind handheld and whole blood point of care test that can rapidly and accurately detect pregnancy in the early stages, helping doctors make faster treatment decisions for women in emergency situations. In addition, Abbott launched its wireless i-STAT handheld system in Europe, which enables faster decision-making for doctors and enhances workflow by transmitting test results to patient medical records in minutes. 

Established Pharmaceuticals
($ in millions)

Note: Prior year financial results have been adjusted to exclude the sales from the developed markets branded generics pharmaceuticals business, which was sold to Mylan on Feb. 27, 2015. Therefore, sales and growth rates shown in the following charts represent continuing operations.









% Change vs. 2Q14



Sales 2Q15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


--


977


977


n/a


46.0


31.3


46.0


31.3

Key Emerging Markets


--


727


727


n/a


43.2


28.3


43.2


28.3

Other


--


250


250


n/a


54.8


40.5


54.8


40.5

 









% Change vs. 1H14



Sales 1H15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


--


1,874


1,874


n/a


44.5


31.5


44.5


31.5

Key Emerging Markets


--


1,380


1,380


n/a


43.9


29.9


43.9


29.9

Other


--


494


494


n/a


46.4


36.1


46.4


36.1

Established Pharmaceuticals sales increased 46.0 percent in the second quarter on an operational basis and 31.3 percent on a reported basis, including an unfavorable 14.7 percent effect of foreign exchange.  Excluding the impact of 2014 acquisitions and foreign exchange, sales increased double digits in the quarter.

Key Emerging Markets include India, Russia, China, Brazil and Colombia, along with several additional markets that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 43.2 percent on an operational basis, driven by above-market growth in India, China, and Colombia. Sales increased 28.3 percent on a reported basis, including an unfavorable 14.9 percent effect of foreign exchange.

In Latin America, sales increased double digits in the quarter on an operational basis with and without the impact of the 2014 acquisition of CFR Pharmaceuticals, which broadened Abbott's presence and product portfolio in the region.

Medical Devices
($ in millions)









% Change vs. 2Q14



Sales 2Q15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


505


784


1,289


3.0


3.1


(11.2)


3.1


(6.1)

Vascular


298


424


722


6.0


1.5


(12.4)


3.2


(5.6)

Diabetes Care


93


185


278


(4.3)


10.1


(5.8)


5.3


(5.3)

Medical Optics


114


175


289


2.0


0.1


(13.4)


0.8


(8.0)


















Vascular Product Lines:

















Coronary Devicesa)


195


363


558


6.9


0.9


(12.8)


2.7


(6.8)

Endovascularb)


70


62


132


3.8


5.4


(9.9)


4.6


(3.1)


















a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b) Includes vessel closure, carotid stents and other peripheral products.

 









% Change vs. 1H14



Sales 1H15




Int'l


Total



U.S.


Int'l


Total


U.S.


Operational


Reported


Operational


Reported

Total


990


1,525


2,515


3.3


1.4


(11.7)


2.1


(6.3)

Vascular


581


839


1,420


6.3


0.5


(12.3)


2.6


(5.5)

Diabetes Care


195


350


545


0.3


6.0


(8.3)


4.1


(5.4)

Medical Optics


214


336


550


(1.5)


(1.0)


(13.4)


(1.2)


(9.2)


















Vascular Product Lines:

















Coronary Devicesa)


380


719


1,099


5.4


(0.4)


(13.0)


1.4


(7.4)

Endovascularb)


137


120


257


8.0


6.1


(8.3)


7.0


(0.2)


















a) Includes DES / BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products.

b) Includes vessel closure, carotid stents and other peripheral products.

Worldwide Medical Devices sales increased 3.1 percent in the second quarter on an operational basis and decreased 6.1 percent on a reported basis, including an unfavorable 9.2 percent effect of foreign exchange.

Worldwide sales of Vascular products increased 3.2 percent in the quarter on an operational basis and decreased 5.6 percent on a reported basis, including an unfavorable 8.8 percent effect of foreign exchange. Sales of Abbott's MitraClip® structural heart device for the treatment of mitral regurgitation increased double digits globally, including strong momentum in the U.S. as Abbott continues to build and shape the market for this first-in-class device. Abbott recently received European approval for Absorb GT1, which combines the Absorb bioresorbable vascular scaffold with a next-generation delivery catheter. Abbott also completed submissions for regulatory approval of Absorb in Japan and the U.S., and expects to submit for regulatory approval in China in the coming months.

Worldwide Diabetes Care sales increased 5.3 percent in the quarter on an operational basis and decreased 5.3 percent on a reported basis, including an unfavorable 10.6 percent effect of foreign exchange. International sales growth was driven by continued uptake of Abbott's revolutionary new FreeStyle Libre Flash Glucose Monitoring System. In the quarter, Abbott submitted FreeStyle Libre Pro, its professional-use version of FreeStyle Libre, for regulatory approval in the U.S. FreeStyle Libre Pro incorporates the same sensor-based technology as FreeStyle Libre and has the potential to change how healthcare providers manage diabetic patients.

Worldwide Medical Optics sales increased 0.8 percent in the quarter on an operational basis and decreased 8.0 percent on a reported basis, including an unfavorable 8.8 percent effect of foreign exchange. Sales growth in the quarter was impacted by market dynamics in the cataract and refractive businesses. Abbott expects improved sales growth over the rest of the year as it continues to drive adoption of recently launched products.

ABBOTT'S FULL-YEAR 2015 EARNINGS-PER-SHARE GUIDANCE RANGE REMAINS UNCHANGED

Abbott's full-year 2015 guidance range for earnings per share from continuing operations, excluding specified items, remains unchanged at $2.10 to $2.20, representing strong growth at the mid-point of the guidance range.

Abbott forecasts net specified items related to continuing operations for the full year 2015 of approximately $0.60 per share. Specified items include intangible amortization expense, charges associated with cost reduction initiatives, and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock.

Including net specified items, projected earnings per share from continuing operations under U.S. Generally Accepted Accounting Principles (GAAP) would be $1.50 to $1.60 for the full year 2015.

ABBOTT DECLARES 366TH CONSECUTIVE QUARTERLY DIVIDEND

On June 12, 2015, the board of directors of Abbott declared the company's quarterly dividend of $0.24 per share. Abbott's cash dividend is payable on Aug. 15, 2015, to shareholders of record at the close of business on July 15, 2015.

Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for 25 consecutive years.

About Abbott:

Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Abbott will webcast its live second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the call will be available after 11 a.m. Central time.

Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors,'' to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2014, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

Second Quarter Ended June 30, 2015 and 2014

(in millions, except per share data)

(unaudited)




2Q15


2Q14


% Change


Net Sales


$5,170


$5,057


2.2










Cost of products sold, excluding amortization expense


2,218


2,288


(3.0)


Amortization of intangible assets


151


133


13.6


Research and development


345


310


11.1


Selling, general, and administrative


1,727


1,649


4.8


Total Operating Cost and Expenses


4,441


4,380


1.4










Operating earnings


729


677


7.5










Interest expense, net


17


17


2.7


Net foreign exchange (gain) loss


5


--


n/m


Other (income) expense, net


(279)


2


n/m

1)

Earnings from Continuing Operations before taxes


986


658


49.8










Taxes on Earnings from Continuing Operations


200


233


(14.5)


Earnings from Continuing Operations


786


425


85.1










Earnings (loss) from Discontinued Operations, net of taxes


(2)


41


n/m

2)









Net Earnings


$784


$466


68.3










Net Earnings from Continuing Operations, excluding 








Specified Items, as described below


$786


$741


6.1

3)









Diluted Earnings per Common Share from:
















Continuing Operations


$0.52


$0.28


85.7










Discontinued Operations


--


0.02


(100.0)

2)









Total


$0.52


$0.30


73.3










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$0.52


$0.49


6.1

3)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,504


1,517





NOTES:


See tables below for an explanation of certain non-GAAP financial information.


n/m = Percent change is not meaningful.


See footnotes below.

 

1)

2015 Other (income) expense includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.



2)

2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations.



3)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of less than $1 million as intangible amortization expense, expenses associated with cost reduction initiatives and expenses related to acquisitions were offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.




2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $316 million, or $0.21 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Abbott Laboratories and Subsidiaries

Consolidated Statement of Earnings

First Half Ended June 30, 2015 and 2014

(in millions, except per share data)

(unaudited)




1H15


1H14


% Change


Net Sales


$10,067


$9,812


2.6










Cost of products sold, excluding amortization expense


4,299


4,562


(5.8)


Amortization of intangible assets


307


260


18.2


Research and development


658


679


(3.0)


Selling, general, and administrative


3,464


3,269


6.0


Total Operating Cost and Expenses


8,728


8,770


(0.5)










Operating earnings


1,339


1,042


28.4










Interest expense, net


33


37


(10.5)


Net foreign exchange (gain) loss


(49)


1


n/m


Other (income) expense, net


(284)


5


n/m

1)

Earnings from Continuing Operations before taxes


1,639


999


63.9










Taxes on Earnings from Continuing Operations


324


350


(7.7)


Earnings from Continuing Operations


1,315


649


102.5










Earnings from Discontinued Operations, net of taxes


25


192


(87.1)


Gain on Sale of Discontinued Operations, net of taxes


1,736


--


n/m


Net Earnings from Discontinued Operations, net of taxes


1,761


192


n/m

2)









Net Earnings


$3,076


$841


n/m










Net Earnings from Continuing Operations, excluding 








Specified Items, as described below


$1,505


$1,276


17.9

3)









Diluted Earnings per Common Share from:
















Continuing Operations


$0.87


$0.42


107.1










Discontinued Operations


1.16


0.13


n/m

2)









Total


$2.03


$0.55


n/m










Diluted Earnings per Common Share from Continuing 








Operations, excluding Specified Items, as described below


$0.99


$0.83


19.3

3)









Average Number of Common Shares Outstanding








Plus Dilutive Common Stock Options 


1,511


1,532





NOTES:


See tables below for an explanation of certain non-GAAP financial information.


n/m = Percent change is not meaningful.


See footnotes below.

 

1)

2015 Other (income) expense includes a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition, both reported as specified items.



2)

2015 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect the after-tax gain of $1.736 billion on the sale of the developed markets branded generics pharmaceuticals and animal health businesses to Mylan on Feb. 27, 2015 and Zoetis on Feb. 10, 2015, respectively; the first-quarter financial results from these businesses up to the date of sale; and a favorable adjustment to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations. 




2014 Earnings and Diluted Earnings per Common Share from Discontinued Operations reflect financial results from the developed markets branded generics pharmaceuticals and animal health businesses, and favorable adjustments to tax expense as a result of the resolution of various tax positions from previous years related to AbbVie operations and the developed markets branded generics pharmaceuticals business.



3)

2015 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $190 million, or $0.12 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and expenses related to acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock and a decrease in the fair value of contingent consideration related to a business acquisition.




2014 Net Earnings from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $627 million, or $0.41 per share, for intangible amortization expense, expenses associated with cost reduction initiatives and tax expense associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

NON-GAAP RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING OPERATIONS


Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Second Quarter Ended June 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)




2Q15



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales










Intangible Amortization


$151


($151)


--



Gross Margin


2,801


185


$2,986


57.8%

R&D


345


(20)


325


6.3%

SG&A


1,727


(67)


1,660


32.1%

Other (Income) Expense, Net


(279)


287


8



Earnings from Continuing Operations before taxes 


986


(15)


971



Taxes on Earnings from Continuing Operations


200


(15)


185



Net Earnings from Continuing Operations


786


--


786



Diluted Earnings per Share from Continuing Operations


$0.52


--


$0.52



 

Specified items reflect intangible amortization expense of $151 million and other expenses of $121 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.



2Q14



Historical GAAP
Adj for Disc Ops1)


Specified
Items


As
Adjusted 


% to
Sales










Intangible Amortization


$133


($133)


--



Gross Margin


2,636


160


2,796


55.3%

R&D


310


(1)


309


6.1%

SG&A


1,649


(95)


1,554


30.7%

Other (Income) Expense, Net


2


(2)


--



Earnings from Continuing Operations before taxes


658


258


916



Taxes on Earnings from Continuing Operations


233


(58)


175



Net Earnings from Continuing Operations


425


316


741



Diluted Earnings per Share from Continuing Operations


$0.28


$0.21


$0.49





1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $133 million and other expenses, primarily associated with cost reduction initiatives of $125 million, as well as tax expense of $101 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

First Half Ended June 30, 2015 and 2014

(in millions, except per share data) 

(unaudited)




1H15



As
Reported
(GAAP) 


Specified
Items


As
Adjusted


% to
Sales










Intangible Amortization


$307


($307)


--



Gross Margin


5,461


371


$5,832


57.9%

R&D


658


(22)


636


6.3%

SG&A


3,464


(109)


3,355


33.3%

Other (Income) Expense, Net


(284)


282


(2)



Earnings from Continuing Operations before taxes 


1,639


220


1,859



Taxes on Earnings from Continuing Operations


324


30


354



Net Earnings from Continuing Operations


1,315


190


1,505



Diluted Earnings per Share from Continuing Operations


$0.87


$0.12


$0.99



 

Specified items reflect intangible amortization expense of $307 million and other expenses of $200 million, primarily associated with cost reduction initiatives and acquisitions, partially offset by a gain on the sale of a portion of Abbott's position in Mylan stock of $207 million and a decrease in the fair value of contingent consideration related to a business acquisition.



1H14



Historical GAAP
Adj for Disc Ops1)


Specified
Items


As
Adjusted 


% to
Sales










Intangible Amortization


$260


($260)


--



Gross Margin


4,990


342


5,332


54.3%

R&D


679


(51)


628


6.4%

SG&A


3,269


(180)


3,089


31.5%

Other (Income) Expense, Net


5


(4)


1



Earnings from Continuing Operations before taxes


999


577


1,576



Taxes on Earnings from Continuing Operations


350


(50)


300



Net Earnings from Continuing Operations


649


627


1,276



Diluted Earnings per Share from Continuing Operations


$0.42


$0.41


$0.83





1)

Historical GAAP financial results, adjusted for the discontinued operations, as previously reported in Abbott's 8-K filing dated Jan. 27, 2015.

 

Specified items reflect intangible amortization expense of $260 million and other expenses, primarily associated with cost reduction initiatives of $317 million, as well as tax expense of $154 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS

A reconciliation of the second-quarter tax rates for continuing operations for 2015 and 2014 is shown below:




2Q15


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$986


$200


20.2%


Specified items


(15)


(15)




Excluding specified items


$971


$185


19.0%























2Q14


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$658


$233


35.4%

1)

Specified items


258


(58)




Excluding specified items


$916


$175


19.0%




1)

Reported tax rate on a GAAP basis includes the impact of tax expense of $101 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2015 and 2014 is shown below:




1H15


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$1,639


$324


19.7%


Specified items


220


30




Excluding specified items


$1,859


$354


19.0%























1H14


($ in millions)


Pre-Tax
Income


Taxes on
Earnings


Tax
Rate


As reported (GAAP)


$999


$350


35.0%

2)

Specified items


577


(50)




Excluding specified items


$1,576


$300


19.0%




2)

Reported tax rate on a GAAP basis includes the impact of tax expense of $154 million associated with a one-time repatriation of 2014 ex-U.S. earnings.

 

Photo - http://photos.prnewswire.com/prnh/20150721/239121-INFO

 

SOURCE Abbott



RELATED LINKS

http://www.abbott.com